167 related articles for article (PubMed ID: 27071778)
21. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
Chen Z; Teo AE; McCarty N
Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
[TBL] [Abstract][Full Text] [Related]
22. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target.
Burger JA; Bürkle A
Br J Haematol; 2007 May; 137(4):288-96. PubMed ID: 17456052
[TBL] [Abstract][Full Text] [Related]
23. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.
Parameswaran R; Yu M; Lim M; Groffen J; Heisterkamp N
Leukemia; 2011 Aug; 25(8):1314-23. PubMed ID: 21483439
[TBL] [Abstract][Full Text] [Related]
24. CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling.
Arnaud MP; Vallée A; Robert G; Bonneau J; Leroy C; Varin-Blank N; Rio AG; Troadec MB; Galibert MD; Gandemer V
Blood; 2015 Oct; 126(15):1802-12. PubMed ID: 26320102
[TBL] [Abstract][Full Text] [Related]
25. Nitric oxide donor upregulation of stromal cell-derived factor-1/chemokine (CXC motif) receptor 4 enhances bone marrow stromal cell migration into ischemic brain after stroke.
Cui X; Chen J; Zacharek A; Li Y; Roberts C; Kapke A; Savant-Bhonsale S; Chopp M
Stem Cells; 2007 Nov; 25(11):2777-85. PubMed ID: 17641243
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced alteration of SDF-1/CXCR4 expression in bone marrow-derived mesenchymal stem cells from adolescents and young adults with acute lymphoblastic leukemia.
Ge J; Hu Y; Gui Y; Hou R; Yang M; Zeng Q; Xia R
J Pediatr Hematol Oncol; 2014 Nov; 36(8):617-23. PubMed ID: 25072364
[TBL] [Abstract][Full Text] [Related]
27. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
Burger M; Glodek A; Hartmann T; Schmitt-Gräff A; Silberstein LE; Fujii N; Kipps TJ; Burger JA
Oncogene; 2003 Nov; 22(50):8093-101. PubMed ID: 14603250
[TBL] [Abstract][Full Text] [Related]
28. [Level of SDF-1/CXCR4 in children with acute leukemia and its significance].
Wen Q; Chen RL; Cai KR; Lin YW
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):324-6. PubMed ID: 21518481
[TBL] [Abstract][Full Text] [Related]
29. Engraftment of human T-cell acute lymphoblastic leukemia in immunodeficient NOD/SCID mice which have been preconditioned by injection of human cord blood.
Dialynas DP; Shao L; Billman GF; Yu J
Stem Cells; 2001; 19(5):443-52. PubMed ID: 11553853
[TBL] [Abstract][Full Text] [Related]
30. General anaesthetics reduce acute lymphoblastic leukaemia malignancies
Jiang C; Gonzalez-Anton S; Li X; Mi E; Wu L; Zhao H; Zhang G; Lu A; Lo Celso C; Ma D
F1000Res; 2022; 11():1491. PubMed ID: 38798305
[TBL] [Abstract][Full Text] [Related]
31. Migration of CXCR4 gene-modified bone marrow-derived mesenchymal stem cells to the acute injured kidney.
Liu N; Tian J; Cheng J; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2677-89. PubMed ID: 23794207
[TBL] [Abstract][Full Text] [Related]
32. Acute lymphoblastic leukemia cells create a leukemic niche without affecting the CXCR4/CXCL12 axis.
de Rooij B; Polak R; van den Berk LCJ; Stalpers F; Pieters R; den Boer ML
Haematologica; 2017 Oct; 102(10):e389-e393. PubMed ID: 28619846
[No Abstract] [Full Text] [Related]
33. [Significance of CXCL12/CXCR4 expression in T-lymphoblastic lymphoma/leukemia].
Yu ZZ; Xi YF; Li J; Bai WQ; Gao N; Bu P
Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):838-843. PubMed ID: 28056298
[No Abstract] [Full Text] [Related]
34. CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment.
Skroblyn T; Joedicke JJ; Pfau M; Krüger K; Bourquin JP; Izraeli S; Eckert C; Höpken UE
J Pathol; 2022 Sep; 258(1):12-25. PubMed ID: 35522562
[TBL] [Abstract][Full Text] [Related]
35. CXCR4 chemokine receptor antagonists: perspectives in SCLC.
Burger JA; Stewart DJ
Expert Opin Investig Drugs; 2009 Apr; 18(4):481-90. PubMed ID: 19335276
[TBL] [Abstract][Full Text] [Related]
36. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
[TBL] [Abstract][Full Text] [Related]
37. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
38. CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance.
Jonart LM; Ostergaard J; Brooks A; Fitzpatrick G; Chen L; Gordon PM
Br J Haematol; 2023 May; 201(3):459-469. PubMed ID: 36535585
[TBL] [Abstract][Full Text] [Related]
39. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
40. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.
Bertolini F; Dell'Agnola C; Mancuso P; Rabascio C; Burlini A; Monestiroli S; Gobbi A; Pruneri G; Martinelli G
Cancer Res; 2002 Jun; 62(11):3106-12. PubMed ID: 12036921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
